Healthcare

Critical guidance on your journey

With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.

Contact advisor

Worldwide

556

deals closed in Healthcare

Worldwide

Explore all our industry-related deals

Go to deals

Banook, backed by Motion Equity, has acquired Fluidda

Healthcare | TMT

Banook, backed by Motion Equity, has acquired Fluidda

Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.

Learn more

Iason GmbH has continued its refinancing efforts with local banks based on an IBR

Healthcare

Iason GmbH has continued its refinancing efforts with local banks based on an IBR

The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.

Learn more

Olyos Group has acquired a controlling stake in NewScience

Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more

“Oaklins’ efforts enabled us to join Banook and significantly enhance our impact on respiratory drug development. Together with an outstanding transaction team, we were able to efficiently integrate into the Banook platform, backed by Motion Equity Partners.”

Jan De Backer

CEO, Fluidda NV

Example: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=de-AT&limit=3&tags=healthcare 
Ours: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=en&limit=1&tags=healthcare

Electronic medical device manufacturer secures buyer for two key subsidiaries in the US and Morocco

DEAL FLASH: Cicor Group has acquired the US and Moroccan subsidiaries of Valtronic. Through this transaction, Valtronic’s shareholders have secured the long-term development and success of the two entities, while Cicor gains access to the US market and doubles its production capacity in Morocco.

Learn more